FindTrial
Sign In

A comparison of hybrid chemotherapy versus hybrid chemotherapy and autotransplant in poor prognosis Hodgkin's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN39498786
Enrollment
Unknown
Registered
2002-08-19
Start date
2001-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma (Hodgkin's) Cancer Lymphoma (Hodgkin's)

Interventions

All patients receive three 28-day cycles of PVACE-BOP (chlorambucil, procarbazine, etoposide, vinblastine, adriamycin, bleomycin and prednisolone), together with co-trimoxazole every 3 weeks for the d

Sponsors

UK Co-ordinating Committee for Cancer Research (UKCCCR)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Histological diagnosis of Hodgkin's disease 2. Prognostic index of at least 0.5 3. Aged under 60 4. No prior chemotherapy or radiotherapy 5. No known significant heart, lung or renal disease 6. No co-existing malignancies apart from localised skin lesions

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026